Coty prices IPO at $17.50 per share
NEW YORK — Coty announced on Thursday the pricing of its initial public offering of 57.1 million shares of its Class A common stock at a price of $17.50 per share.
Coty’s Class A common stock began trading on the New York Stock Exchange on Thursday under the ticker symbol COTY. As reported, the shares offered are being sold by existing Coty stockholders, and the beauty company will not receive any of the proceeds of the offering.
These existing stockholders also have granted the underwriters an option for 30 days to purchase an additional 8.6 million shares of Class A common stock at the initial offering price less the underwriting discount.
Michele Scannavini, CEO of Coty, accompanied by Coty’s executive committee and a group of business partners, celebrated the company’s first day of trading by ringing the NYSE Opening Bell and visiting the trading floor for the stock opening.
“Today marks an important milestone in the continued growth of Coty, as we list on the prestigious New York Stock Exchange,” Scannavini said. “We are proud of Coty’s many accomplishments and proven industry track record, and are enthusiastic to embark on this exciting new chapter.”
As of late morning, shares were trading at $17.22, down 1.6%.
National HIV Testing Day: Walgreens to provide free HIV testing in nearly 175 stores across 54 cities
WALGREENS — Walgreens and Greater Than AIDS are teaming with health departments and local AIDS organizations across the country to provide free HIV testing in support of National HIV Testing Day, June 27, according to a release from The Henry J. Kaiser Family Foundation.
This marks the third consecutive year Walgreens has teamed with Greater Than AIDS and local organizations to help bring free HIV testing to communities. This year, more than three times the number of stores and testing partners are participating compared with 2012.
“Access to testing, education and care are critical when it comes to the treatment and prevention of this complex condition,” stated Glen Pietrandoni, senior manager of virology at Walgreens. “We have supported people living with HIV/AIDS since the beginning of the epidemic more than 30 years ago and will continue to be a trusted resource. Through this significant collaboration, we can help even more people get, stay and live well.”
“Frequent testing is the first step towards early treatment and preventing the spread of HIV/AIDS,” stated Tina Hoff, SVP and director of health communication and media partnerships, Kaiser Family Foundation, a founding partner of Greater Than AIDS. “Greater than AIDS is pleased to once again mark National HIV Testing Day by collaborating with Walgreens and local and state governments to broaden access to HIV tests for people in many of the nation’s hardest-hit communities.”
Testing locations include nearly 175 Walgreens stores in 54 cities across 22 states. Hundreds of additional Walgreens stores in the participating communities will help publicize the free testing through in-store marketing and other programs. Walgreens also will help promote National HIV Testing Day with special messages on June 27 on its Times Square digital display in New York.
More than 130 state and local health departments and AIDS service organizations are coordinating the testing and providing results on-site at participating Walgreens locations, as well as supporting outreach.
Free HIV tests will be available June 27-28 from 3 p.m. to 7 p.m., and June 29 from 9 a.m. to 2 p.m. at select Walgreens locations in major metropolitan areas including Atlanta, Baltimore, Boston, Chicago, Detroit, Houston, Los Angeles, Miami, New Orleans, New York, San Francisco and Washington.
For more information, including a complete list of participating Walgreens locations, go to GreaterThan.org/Walgreens.
Throughout the year, Walgreens and Greater Than AIDS distribute HIV informational resources at 700 Walgreens drugstores in heavily affected communities. Designated by Walgreens as “Centers of Excellence,” these stores have pharmacists on hand to offer one-on-one medication counseling and other support services that provide customers living with HIV/AIDS — and their families — with compassionate, confidential care.
FDA approves Amgen’s Xgeva for giant cell tumor of the bone
SILVER SPRING, Md. – The Food and Drug Administration has approved a drug made by Amgen for treating a rare and usually noncancerous bone tumor, the agency said Thursday.
The FDA announced the approval of Xgeva (denosumab) for adults and some adolescents with giant cell tumor of the bone, also known as GCTB. In most cases, GCTB, which usually occurs in adults age 20 years to 40 years, does not spread to other parts of the body, but destroys bone tissue as it grows, causing pain, limited range of motion and fractures. In some rare cases, it can turn into a cancerous tumor and spread to the lungs, the FDA said.
"Today’s approval of Xgeva provides a needed treatment option for patients with GCTB who are not surgical candidates or who would otherwise have to undergo extensive, life-altering surgery," FDA Office of Hematology and Oncology Products director Richard Pazdur said.